2022
Management of Patients on Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Peri-Endoscopic Period: A Clinical Practice Guideline Dissemination Tool
Barkun AN, Douketis J, Noseworthy PA, Laine L, Telford JJ, Abraham NS. Management of Patients on Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Peri-Endoscopic Period: A Clinical Practice Guideline Dissemination Tool. The American Journal Of Gastroenterology 2022, 117: 513-519. PMID: 35354773, DOI: 10.14309/ajg.0000000000001688.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2021
Antiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After Endoscopic Sphincterotomy
Zakko A, Zakko L, Grimshaw AA, Laine L. Antiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After Endoscopic Sphincterotomy. Digestive Diseases And Sciences 2021, 67: 4161-4169. PMID: 34796411, DOI: 10.1007/s10620-021-07302-w.Peer-Reviewed Original ResearchMeSH KeywordsAdultAspirinCholangiopancreatography, Endoscopic RetrogradeHemorrhageHumansPlatelet Aggregation InhibitorsSphincterotomy, EndoscopicConceptsEndoscopic retrograde cholangiopancreatographyPost-sphincterotomy bleedingAntiplatelet monotherapyInclusion criteriaRisk of bleedingROBINS-I toolNewcastle-Ottawa ScaleHigh-quality studiesRandom-effects modelBackgroundClinical guidelinesAntithrombotic therapyAdult patientsCohort studyEndoscopic sphincterotomyPrimary outcomeAntiplatelet agentsOvid EmbaseRetrograde cholangiopancreatographyCochrane LibraryOvid MEDLINEMonotherapyMethodological qualityBleedingUnique citationsPatientsGastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy ∗
Bittl JA, Laine L. Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy ∗. Journal Of The American College Of Cardiology 2021, 79: 129-131. PMID: 34752903, DOI: 10.1016/j.jacc.2021.10.027.Commentaries, Editorials and LettersMeSH KeywordsAspirinClopidogrelDrug-Eluting StentsDual Anti-Platelet TherapyHumansPlatelet Aggregation Inhibitors
2016
No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents
Zakko L, Rustagi T, Douglas M, Laine L. No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents. Clinical Gastroenterology And Hepatology 2016, 15: 46-52. PMID: 27464591, DOI: 10.1016/j.cgh.2016.07.017.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overFemaleGastrointestinal HemorrhageHumansMaleMiddle AgedPlatelet Aggregation InhibitorsPlatelet TransfusionRetrospective StudiesSecondary PreventionTreatment OutcomeYoung AdultConceptsGastrointestinal bleedingAntiplatelet agentsPlatelet transfusionsCardiovascular eventsNon-variceal upper gastrointestinal bleedingYale-New Haven HospitalRecurrent gastrointestinal bleedingSerious gastrointestinal bleedingMajor cardiovascular eventsRetrospective cohort studySevere gastrointestinal bleedingUpper gastrointestinal bleedingLower blood pressureMultivariable regression analysisHigher heart rateLack of benefitRecurrent bleedingBaseline characteristicsCohort studyBlood pressurePrimary outcomeSuch patientsHemoglobin levelsMultivariable analysisIntensive careEfficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial
Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DL, Investigators C. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. The American Journal Of Medicine 2016, 129: 1002-1005. PMID: 27143321, DOI: 10.1016/j.amjmed.2016.03.042.Peer-Reviewed Original ResearchConceptsDual antiplatelet therapyProton pump inhibitorsAcute coronary syndromePercutaneous coronary interventionCardiovascular eventsCoronary syndromeCoronary interventionGastrointestinal eventsPercutaneous coronary intervention-treated patientsSafety of PPIsUnadjusted Cox proportional hazards modelCox proportional hazards modelDays of randomizationMajor cardiovascular eventsComposite cardiovascular eventsSubset of patientsSafety of omeprazoleProportional hazards modelGastroprotective strategiesMedian followPPI therapyAntiplatelet therapyFrequent indicationHazards modelPatientsLong-Term PPI Use: Balancing Potential Harms and Documented Benefits
Laine L, Nagar A. Long-Term PPI Use: Balancing Potential Harms and Documented Benefits. The American Journal Of Gastroenterology 2016, 111: 913. PMID: 27113114, DOI: 10.1038/ajg.2016.156.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsProton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy
Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP, Investigators C. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. Journal Of The American College Of Cardiology 2016, 67: 1661-1671. PMID: 27012778, DOI: 10.1016/j.jacc.2015.12.068.Peer-Reviewed Original ResearchMeSH KeywordsAgedAspirinClopidogrelDose-Response Relationship, DrugDrug Therapy, CombinationDyspepsiaFemaleGastrointestinal HemorrhageHumansIntestinal ObstructionIntestinal PerforationMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationOmeprazolePainPeptic UlcerPlatelet Aggregation InhibitorsProspective StudiesProton Pump InhibitorsStrokeTiclopidineConceptsDual antiplatelet therapyLow-dose aspirinProton pump inhibitorsMajor adverse cardiac eventsAdverse cardiac eventsPPI therapyAntiplatelet therapyAspirin usersGastrointestinal eventsCardiac eventsGI eventsMeier estimatesArtery diseaseCardiovascular endpointsLow-dose aspirin usersPrimary cardiovascular endpointUpper GI eventsHigh-dose aspirinPeripheral artery diseasePercutaneous coronary interventionCoronary artery diseaseHigh rateAspirin groupBlinded gastroenterologistsAspirin dose
2015
The effects of proton pump inhibition on patient‐reported severity of dyspepsia when receiving dual anti‐platelet therapy with clopidogrel and low‐dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial
Vardi M, Cryer BL, Cohen M, Lanas A, Schnitzer TJ, Lapuerta P, Goldsmith MA, Laine L, Doros G, Liu Y, McIntosh AI, Cannon CP, Bhatt DL. The effects of proton pump inhibition on patient‐reported severity of dyspepsia when receiving dual anti‐platelet therapy with clopidogrel and low‐dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. Alimentary Pharmacology & Therapeutics 2015, 42: 365-374. PMID: 26032114, PMCID: PMC4494867, DOI: 10.1111/apt.13260.Peer-Reviewed Original ResearchConceptsDual anti-platelet therapyAnti-platelet therapyGastrointestinal Event TrialLow-dose aspirinNonpain symptomsEvents trialPatient-reported outcome dataPercent of patientsPatient-reported symptomsPatient-reported outcomesPatient-reported severityOmeprazole groupProphylactic omeprazoleCardiovascular safetyGastrointestinal bleedingPain intensityClinical eventsOmeprazole useClinical significanceOutcome dataAssessment QuestionnaireClopidogrelDyspepsiaTherapyPatients
2013
Gastroprotection in Low-Dose Aspirin Users for Primary and Secondary Prevention of ACS: Results of a Cost-Effectiveness Analysis Including Compliance
de Groot NL, van Haalen HG, Spiegel BM, Laine L, Lanas A, Focks JJ, Siersema PD, van Oijen MG. Gastroprotection in Low-Dose Aspirin Users for Primary and Secondary Prevention of ACS: Results of a Cost-Effectiveness Analysis Including Compliance. Cardiovascular Drugs And Therapy 2013, 27: 341-357. PMID: 23417566, DOI: 10.1007/s10557-013-6448-y.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAspirinCost-Benefit AnalysisDrug Therapy, CombinationGastrointestinal HemorrhageHealth Care CostsHumansMaleMiddle AgedModels, TheoreticalPatient CompliancePlatelet Aggregation InhibitorsPrimary PreventionProton Pump InhibitorsQuality-Adjusted Life YearsSecondary PreventionConceptsAcute coronary syndromeProton pump inhibitorsUpper GI bleedingSecondary preventionGI bleedingASA monotherapyPPI complianceElevated riskLow-dose ASA usersLow-dose aspirin usersUpper GI side effectsGI side effectsUpper gastrointestinal complicationsCombination of ASABase-case patientProbabilistic sensitivity analysesCost-effectiveness analysisASA usersGastrointestinal complicationsGastroprotective strategiesAspirin usersCoronary syndromePPI useACS eventCase patients
2011
Proton Pump Inhibitor Co-therapy With Clopidogrel: Is There GI Benefit or Cardiovascular Harm?
Laine L. Proton Pump Inhibitor Co-therapy With Clopidogrel: Is There GI Benefit or Cardiovascular Harm? Gastroenterology 2011, 140: 769-772.e2. PMID: 21266209, DOI: 10.1053/j.gastro.2011.01.024.Commentaries, Editorials and Letters
2010
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal Of Gastroenterology 2010, 105: 2533. PMID: 21131924, DOI: 10.1038/ajg.2010.445.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAnti-Inflammatory Agents, Non-SteroidalAryl Hydrocarbon HydroxylasesAspirinCardiovascular DiseasesClopidogrelCytochrome P-450 CYP2C19Drug InteractionsDrug Therapy, CombinationGastrointestinal HemorrhageHistamine H2 AntagonistsHumansPiperazinesPlatelet Aggregation InhibitorsPrasugrel HydrochlorideProton Pump InhibitorsPurinergic P2Y Receptor AntagonistsRisk FactorsThienopyridinesThiophenesTiclopidineACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Documents A, Abraham N, Hlatky M, Antman E, Bhatt D, Bjorkman D, Clark C, Furberg C, Johnson D, Kahi C, Laine L, Mahaffey K, Quigley E, Scheiman J, Sperling L, Tomaselli G. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal Of The American College Of Cardiology 2010, 56: 2051-2066. PMID: 21126648, DOI: 10.1016/j.jacc.2010.09.010.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Members W, Abraham N, Hlatky M, Antman E, Bhatt D, Bjorkman D, Clark C, Furberg C, Johnson D, Kahi C, Laine L, Mahaffey K, Quigley E, Scheiman J, Sperling L, Tomaselli G. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation 2010, 122: 2619-2633. PMID: 21060077, DOI: 10.1161/cir.0b013e318202f701.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAnti-Inflammatory Agents, Non-SteroidalAryl Hydrocarbon HydroxylasesAspirinCardiovascular DiseasesClopidogrelCytochrome P-450 CYP2C19Drug InteractionsDrug Therapy, CombinationGastrointestinal HemorrhageHistamine H2 AntagonistsHumansPiperazinesPlatelet Aggregation InhibitorsPrasugrel HydrochlorideProton Pump InhibitorsPurinergic P2Y Receptor AntagonistsRisk FactorsThienopyridinesThiophenesTiclopidineClopidogrel with or without Omeprazole in Coronary Artery Disease
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal Of Medicine 2010, 363: 1909-1917. PMID: 20925534, DOI: 10.1056/nejmoa1007964.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsDual antiplatelet therapyUpper gastrointestinal bleedingAntiplatelet therapyCardiovascular eventsGastrointestinal bleedingOvert upper gastrointestinal bleedingPrimary cardiovascular end pointEnd pointEvent ratesEfficacy of clopidogrelSymptomatic gastroduodenal ulcersCardiovascular end pointsComposite of deathNonfatal myocardial infarctionSerious adverse eventsCoronary artery diseaseHigh-risk subgroupsRisk of diarrheaCardiovascular causesGastrointestinal complicationsGastrointestinal eventsOccult bleedingAntithrombotic therapyAdverse events
2009
Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?
Laine L, Hennekens C. Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction? The American Journal Of Gastroenterology 2009, 105: ajg2009638. PMID: 19904241, DOI: 10.1038/ajg.2009.638.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProton pump inhibitorsClopidogrel usersCV eventsClopidogrel efficacyPump inhibitorsObservational studyPresence of PPIsTrial of omeprazoleHealth care providersCytochrome P450Clopidogrel actionClopidogrel interactionCardiovascular eventsGastrointestinal bleedingRandomized trialsConcomitant useSurrogate markerRecommendations stateClopidogrelCurrent evidenceCYP2C19 functionUS FoodDrug AdministrationPlatelet aggregationActive metabolite
2008
Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents
Chan FK, Abraham NS, Scheiman JM, Laine L. Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. The American Journal Of Gastroenterology 2008, 103: ajg2008576. PMID: 18853980, DOI: 10.1111/j.1572-0241.2008.02200.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalCardiovascular DiseasesGastrointestinal DiseasesHumansPlatelet Aggregation InhibitorsConceptsNonselective nonsteroidal antiinflammatory drugsNonsteroidal antiinflammatory drugsGI risk factorsNonsteroidal anti-inflammatory drugsCV riskHigh CV riskProton pump inhibitorsAnti-inflammatory drugsRisk factorsCyclooxygenase-2- selective nonsteroidal antiinflammatory drugsSelective nonsteroidal antiinflammatory drugsCardiovascular safety issuesMultidisciplinary international panelPatient's CV riskClinical practice recommendationsManagement of patientsAnti-platelet agentsGI complicationsCardiovascular effectsGI riskInternational working partyPump inhibitorsTreatment strategiesAntiinflammatory drugsPatients
2007
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, Committee F. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. The Lancet 2007, 369: 465-473. PMID: 17292766, DOI: 10.1016/s0140-6736(07)60234-7.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalArthritisArthritis, RheumatoidAspirinCyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDiclofenacEtoricoxibFemaleGastrointestinal DiseasesGastrointestinal HemorrhageHumansMaleMiddle AgedOsteoarthritisPeptic UlcerPlatelet Aggregation InhibitorsProton Pump InhibitorsPyridinesSulfonesConceptsProton pump inhibitorsNon-steroidal anti-inflammatory drugsUpper gastrointestinal safetyLow-dose aspirinClinical eventsGastrointestinal safetyRheumatoid arthritisUncomplicated eventsTraditional non-steroidal anti-inflammatory drugsConcomitant proton pump inhibitorsLow-dose aspirin useCOX-2 selective inhibitorsTraditional NSAID diclofenacAnti-inflammatory drugsStandard clinical practiceSelective inhibitorGastrointestinal eventsMultinational EtoricoxibAspirin useGastrointestinal outcomesTreat analysisProtective therapyPump inhibitorsCyclo-oxygenaseNSAID diclofenac
2006
Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials
McQuaid KR, Laine L. Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials. The American Journal Of Medicine 2006, 119: 624-638. PMID: 16887404, DOI: 10.1016/j.amjmed.2005.10.039.Peer-Reviewed Original ResearchConceptsLow-dose aspirinAspirin/clopidogrelMajor GI bleedingMajor bleedingGI bleedingAdverse eventsIntracranial bleedingRelative riskSystematic reviewMajor bleeding episodesMajor gastrointestinal bleedingRelevant adverse eventsRisk of GIAbsolute risk increaseRandomized Controlled TrialsDay aspirinMajor GIBleeding episodesCardiovascular prophylaxisGastrointestinal bleedingAntiplatelet agentsControlled TrialsWeighted incidenceAbsolute riskClopidogrel